Juan Granada and Nicolas Van Mieghem share an overview of the data presented on day 2 of NY Valves.

Primary results of the ENCIRCLE trial led to approval of the M3 device by the US Food and Drug Administration as the first ...

Cardiovascular surgery seems to be just as safe in patients with concomitant multiple sclerosis (MS) as in those without the ...

While the dataset is incomplete, the death and stroke curves appear to separate at 2 years, notes Philippe Généreux.

In a simulated cohort of patients with subclinical device-detected atrial fibrillation (AF), broad use of direct oral ...

“TAVR with the Sapien 3 platform demonstrated comparable 7-year durability to surgery, supporting its use as a treatment option in lifetime management of low-risk patients with symptomatic severe AS,” ...

Medically tailored meals, nurses front and center for prevention, GLP-1s and muscle mass in cardiac rehab, and more.

Attendees will find 30 late-breaking clinical science and innovation presentations, the LAAC Summit, puppies, and more.

NY Valves 2026 Livestream This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

The proposed decision memo also paves the way for triaging by chart review and enhancing flexibility for heart team decisions ...

Cost-related issues have decreased as many drugs have become generic, but adherence still remains a challenge.

The combination of consistent strength training, aerobic activity, and limited sedentary time yielded the greatest benefits.